The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

JD SPORTS reported pre-tax profits of £917.2 million (€1.1 billion) in 2023 and hoped for 2024 earnings of £1 billion (€1.19 ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...

GSK plc (NYSE: GSK) and IDRx, Inc. (IDRx) recently announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Prime Minister Christopher Luxon has taken aim at a “culture of saying no” in his State of the Nation address, arguing it is ...